Valuation: Makers Laboratories Limited

Market Cap 80Cr 83.64L 73.16L 67.48L 62.33L 1.18Cr 1.2Cr 8.06Cr 3.17Cr 39Cr 3.14Cr 3.07Cr 135.1Cr P/E 2024
-10.6x
P/E 2025 10.2x
Enterprise Value 85Cr 88.7L 77.58L 71.56L 66.09L 1.25Cr 1.28Cr 8.55Cr 3.36Cr 42Cr 3.33Cr 3.26Cr 143.26Cr EV / Sales 2024
0.78x
EV / Sales 2025 0.67x
Free-Float
32.66%
Yield 2024 *
-
Yield 2025 -
26/05 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
10/02 Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
07/11 Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
29/25/29 CARE Affirms BBB+ Rating on Makers Laboratories' Long-Term Bank Financing; Outlook Stable MT
08/25/08 Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
08/25/08 Makers Laboratories Returns to Consolidated Profit in Fiscal Q1; Shares Slide MT
26/25/26 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
29/24/29 Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
06/24/06 Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
23/24/23 Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories MT
23/24/23 Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
23/24/23 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
15/24/15 Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024 CI
1 day-3.80%
1 week-2.11%
Current month+1.65%
1 month+4.40%
3 months-7.43%
6 months+26.01%
Current year+25.48%
1 week 145
Extreme 145
164.95
1 month 140.95
Extreme 140.95
168.5
Current year 112.1
Extreme 112.1
186.7
1 year 109
Extreme 109
186.7
3 years 98.05
Extreme 98.05
230
5 years 94
Extreme 94
238
10 years 23.2
Extreme 23.2
344.8
Manager TitleAgeSince
Chief Executive Officer 51 11/08/2011
Director of Finance/CFO 59 30/10/2017
Compliance Officer - 23/05/2024
Director TitleAgeSince
Director/Board Member 79 29/04/2009
Chairman 77 28/03/2019
Director/Board Member 51 11/08/2011
Change 5-day change 1-year change 3-year change Capi.($)
-3.80%-2.11%-3.23%+27.14% 91.72L
-0.17%+1.61%+15.76%+80.51% 4.87TCr
+1.04%-1.02%+67.19%+116.18% 3.64TCr
-0.13%-1.29%-3.07%+40.05% 1.22TCr
-0.71%+0.89%+17.48%+96.77% 1.2TCr
-0.76%+0.38%+31.49%+124.03% 904.09Cr
+0.75%-0.82%+18.53%+42.99% 709.46Cr
-0.86%+0.37%+50.57%-3.02% 706.36Cr
+0.69%+3.25%+4.67%+240.43% 675.48Cr
+5.45%-7.36%-17.51%+14.39% 610.48Cr
Average +0.15%-0.59%+18.19%+77.95% 1.45TCr
Weighted average by Cap. +0.34%+0.09%+28.08%+88.86%

Financials

2024 2025
Net sales 104.39Cr 1.09Cr 95.74L 88.31L 81.56L 1.55Cr 1.57Cr 11Cr 4.14Cr 51Cr 4.11Cr 4.02Cr 176.79Cr 120.75Cr 1.27Cr 1.11Cr 1.02Cr 94.34L 1.79Cr 1.82Cr 12Cr 4.79Cr 59Cr 4.75Cr 4.65Cr 204.5Cr
Net income -6.26Cr -7L -6L -5L -5L -9L -9L -63.31L -24.86L -3.09Cr -24.66L -24.12L -11Cr 7.49Cr 8L 7L 6L 6L 11.1L 11.29L 75.71L 29.73L 3.69Cr 29.49L 28.85L 13Cr
Net Debt 15Cr 15.59L 13.64L 12.58L 11.62L 22.04L 22.41L 1.5Cr 59.02L 7.32Cr 58.53L 57.26L 25Cr 4.82Cr 5L 4L 4L 4L 7L 7L 48.71L 19.13L 2.37Cr 18.97L 18.56L 8.16Cr
Logo Makers Laboratories Limited
Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company's segments include Pharmaceutical and Chemical Manufacturing. It has one manufacturing unit in India manufacturing formulations for the Indian market. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimesulide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). It also offers a range of diabetic and hypertensive drugs, including Voglibose, Gli-me range (Glimepiride + Metformin +Pioglitazone), and Hypernorm range (Telmisartan). Its product categories include Inspira - Retail Packs and Experia - Bulk Packs. Its Inspira - Retail Packs include anthelmintics, anti-biotics, anti-emetics and anti-nauseants. Its Experia - Bulk Packs include betamethasone 0.5 mg tablets, chloramphenicol capsules 250 mg and diclofenac 50 mg tablets.
Employees
131
Date Price Change Volume
10/26/10 ₹148.25 -3.80% 7,110
09/26/09 ₹154.10 +1.55% 742
08/26/08 ₹151.75 +1.10% 7,234
07/26/07 ₹150.10 -1.15% 166
06/26/06 ₹151.85 +0.26% 2,404
  1. Stock Market
  2. Stocks
  3. MAKERSL6 Stock